Investment Thesis
Lunai Bioworks faces imminent solvency crisis with negative stockholders equity of -$9.6M, indicating liabilities exceed assets. The company burns $3.4M in operating cash annually against nearly zero revenue ($20.9K), providing less than one year of runway from remaining cash reserves. With a current ratio of 0.19x and no meaningful revenue generation, going-concern risk is critical.
Strengths
- Retains $3.2M in cash providing short-term liquidity runway
- Minimal long-term debt ($540K) reduces leverage obligations
- Low ongoing capital requirements suggest reduced burn from non-essential spending
Risks
- Negative stockholders equity of -$9.6M indicates technical insolvency and balance sheet collapse
- Operating cash burn of -$3.4M annually with <1 year cash runway creates urgent refinancing/shutdown timeline
- Revenue collapse to $20.9K reveals failed commercialization with no viable business model or product-market traction
- Current ratio of 0.19x signals inability to meet current liabilities, creating imminent liquidity crisis
- Zero insider Form 4 activity over 90 days suggests absent insider confidence in survival prospects
- Going concern risk elevated; company likely requires dilutive emergency financing or restructuring
Key Metrics to Watch
- Cash balance depletion rate and remaining runway months
- Any financing announcements or dilutive offerings
- Revenue inflection or shutdown/merger announcements
Financial Metrics
Revenue
20.9K
Net Income
-1.6M
EPS (Diluted)
$-0.07
Free Cash Flow
-3.4M
Total Assets
9.9M
Cash
3.2M
Profitability Ratios
Gross Margin
100.0%
Operating Margin
-31,320.0%
Net Margin
-7,409.9%
ROE
N/A
ROA
-15.7%
FCF Margin
-16,466.5%
Balance Sheet & Liquidity
Current Ratio
0.19x
Quick Ratio
0.19x
Debt/Equity
N/A
Debt/Assets
196.9%
Interest Coverage
-8.65x
Long-term Debt
540.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:43:18.828198 |
Data as of: 2026-03-31 |
Powered by Claude AI